New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareLivagen vs Semaglutide

Livagen vs Semaglutide

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Livagen
GLP-1 / Weight Loss Agonists
Semaglutide
Summary
Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed for type 2 diabetes that has proven remarkably effective for weight loss. Clinical trials show average 15–20% body weight reduction. It is marketed as Ozempic (diabetes) and Wegovy (weight management).
Half-Life
Short (minutes); gene-regulatory effects are sustained
~7 days
Admin Route
SubQ, Oral
SubQ, Oral
Research
Typical Dose
10 mg per day
0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg
Frequency
Daily for 10–30 days
Once weekly, subcutaneous
Key Benefits
  • Supports hepatocyte regeneration and liver tissue repair
  • Normalizes liver cell protein synthesis
  • Immune modulation via thymic activity
  • Potential benefits in chronic hepatitis and liver aging
  • Anti-aging effects on hepatic tissue
  • May support liver recovery after toxic insult or alcohol damage
  • Complementary to NAD+ and glutathione in liver health protocols
  • Average 15–20% body weight reduction in clinical trials (STEP trials)
  • Significant reduction in appetite and food cravings
  • Improvement in blood sugar control and insulin sensitivity
  • Reduces cardiovascular risk (SELECT trial: 20% reduction in MACE)
  • May reduce risk of kidney disease
  • Improves metabolic markers (cholesterol, blood pressure)
  • FDA-approved — extensively studied with robust safety data
  • Weekly dosing convenience
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hepatotoxic effects reported at standard doses
  • Nausea (most common, especially during titration)
  • Vomiting
  • Diarrhea or constipation
  • Abdominal discomfort
  • +4 more
Stacks With